Pure Health Systems

  Pure Health Systems
 
 
 
 
 
Natural Wholistic Care for a Natural You

ENZYME RESEARCH PAPER REFERENCES!

SEARCH THIS SITE
970-731-9724
   
1. Griffin, S. M., et al, Acid resistant lipase as replacement therapy in chronic exocrine insufficiency: a study in dogs, Gut, 30:1012-1015, 1989.

2. Mackie, R D., et al, Malabsorption of starch in pancreatic sufficiency, Gastroenterology, 80:1220, 1981

3. DiMagno, E. P., et al, Relations between pancreatic enzyme outputs and malabsorption in severe pancreatic insufficiency, N. Eng. J. Med., 228:813-815, 1973

4. Fitzgerald, D. E., et al Relief of chronic arterial obstruction using intravenous brinase, Scand. J. Thor. Cardiovasc. Surg., 13:327-332,1979.

5. Bergkvist, R and Svard, P. C., Studies on the thrombolytic effect of a protease from Aspergillus oryzae, Acta Physiol.. Sand., 60:363-371,1964

6. Fitzgerald, D. E., and Frisch, E. P., Relief of chronic peripheral artery obstruction by intravenous brinase, Irish Med. Ass., 66:3, 1973.

7. Lund, F., et al, Thrombolytic treatment with i. v. brinase in advance arterial obliterative disease, Angiology, 26:534, 1975.

8. Verstraefe, M. and Verhaege, R, Clinical study if brinase, a proteolytic enzyme from Aspergillus oryzae, 19th Annual Congr. Intern,. Coll. Angiology, Dublin, Ireland, 1977.

9. Kiesslling, H. and Svenson, R, Influence of an enzyme from Aspergillus oryzae, Protease 1, on some components of the fibrinolytic system, Acta Chem. Scand., 24: 569-579, 1970.

10. Frisch, E. P., et al, Dosage of i. v. brinase in man based on brinase inhibitor capacity and coagulation studies, Angiology, 26:557, 1975.

11. Roschlau, H. E. and Fisher, A.M., Thrombolytic therapy with local perfusions of CA-7 (fibrinolytic enzyme from Aspergillus oryzae) in the dog, Angiology, 17:670-682, 1966.

12. Larson, L. J., et al Properties of the complex between alpha-2-macro-globulin and brinase, a proteinase from Aspergillus oryzae with thrombolytic effect, thrombosis Research, 49:55-68, 1988.

13. Verhaege, R, et al, Clinical trial of brinase and anticoagulants as a method of treatment for advanced limb ischemia, Eur. J. Clin. Pharmacol., 16: 165- 170, 1979.

14. Vanhove, P., et al, Action of brinase on human fibrinogen and plasminogen. Thrombos Haemostas., 42: 571-581, 1979

15. Frisch, E. P. and Blomback, M., Blood coagulation studies in patients treated with brinase. In: Progress in Chemical Fibrinolysis and Thrombolysis. Vol. IV, J. F. Davidson (Ed.), Edinburgh: Churchill-Livingstone, pp. 184- 187, 1979

16. Phelan, J. J., et al, Coeliac disease: The abolition of gliadin toxicity by enzymes from Aspergillus niger, Clin. Sci. Molec. Med., 53: 35-43,1977.

17. McCarthy, C. F., Nutritional defects in patients with malabsorption, Proc. Nutr. Soc., 35:37- 40,1976.

18. Gardner, M. L. G., Gastrointestinal absorption of intact proteins, Ann. Rev. Nutr., 8:329-350,1988.

19. Gardner, M. L. G., intestinal assimilation of intact peptides and proteins from the diet - A neglected field?, Biol. Rev., 59:289-331,1984.

20. Warshaw, A. L., et a, Protein uptake by the intestine: Evidence for absorption of intact macromolecule's, Gastroenterology, 66: 987-992,1974.

21. Udall, J. N. and Walker, W. A., The physiologic and pathologic basis for the transport of macromolecule's across the intestinal tract, J. Pediatr.. Gastroentarol. Nutr., :295-301,1982.

22. Loehry, C. A., et al Permeability of the small intestine to substances of different molecular weight, Gut, 11 :446-470, 1970.

23. Hemmings W. A. and Williams, E. W., Transport of large breakdown products of dietary protein through the gut wall Gut, 19:715-723, 1978.

24. Jacobson, I., et al Human beta-lactalbumin as a marker of rnacromolecular absorption, Gut, 27: 1029-1034, 1986.

25. Menzies, I. S., Transmucosal passage of inert molecules in health and disease, In Intestinal Absorption and Secretion, E. Skadhauge and K Heintze, eds., MTP Press, Lancaster, pp. 527-543, 1984.

26. Wolf, J. L., et al Intestinal M cells: A pathway for entry of retrovirus into the host, Science, 212:471-472, 1981.

27. Ormistron B. J., Clinical effects of TRH and TSH after i. v. and oral administration in normal volunteers and patients with thyroid disease, In Thytropin Releasing Hormone (Frontiers of Hormone) Research, Vol. 1), R. Hall, et al, eds., Karger, Basel pp. 45-52, 1972.

28. Amoss, M., et al, Release of gonadotrophins by oral administration of synthetic LRF or a tripeptidle fragment of LRF, J. Clin. Endocrinol. Metab., 35: 135-177, 1972.

29. Siefert, J., et al, Mucosal permeation of Macromolecules and particles, See Ref 31, pp. 505-513.

30. Laskowski M., et al, Effect of trypsin inhibitor on passage of insulin across the intestinal barrier, Science, 127: 1115-1116, 1958.

31. Liebow, C. and Rothman, S. S., Enteropancreatic circulation of digestive enzymes, Science, 189:472-474,1975

32. Bockman, D. E. and Winborm, W. B., Light and electron microscopy of intestinal ferritin absorption: Observations in sensitized and non-sensitized hamsters, Anat. Rec.,155:603- 622,1966.

33. Andre, C., et al Interference of oral immunization with the intestinal absorption of heterologous albumin, Eur. J. Immunol., 4:701-704, 1974.

34. Dannaeus A., et al, Intestinal uptake of ovalbumin in malabsorption and food allergy in relation to serum lgG antibody and orally administrated sodium chromoglycate, Clin. Allergy, 9: 263-270,1979.

35. Ferguson, A. and Caldwell, F., Precipitins to dietary proteins in serum and upper GI secretion of coeliac children, Br. Med. J., 1 :75-77,1972.

36. Husby, S., et al Passage of dietary antigens into the blood of children with coeliac disease: Quantification and size distribution of absorbed antigens, Gut, 28:1062-1072,1987.

37. Husby, S., et al Passage of undergrade dietary antigen into the blood of healthy adults: further characterization of the kinetics of uptake and the size distribution of the antigen. Scand. J. Immunol.,24:447-455,

1986. 38. Walker, W. A., Antigen absorption from the small intestine and gastrointestinal disease, Pediatr. Clin., North Am., 22:731-746, 1975.

39. Hamilton, I., et al, Small intestinal permeability in dermatological disease, Q. J. Med., 56:559-567, 1985

40. Bjarnason, I., et al, Intestinal permeability in celiac sprue, dermatitis herpetiformis, schizophrenia and atopic eczema, Gastroenterology, 86: 1029, 1984.

41. Heatley, RV., et al, Inflammatory bowel disease, In Gut Defenses in Clinical Practice, M. S. Losowsky and R V. Heatley, eds., Churchill Livingstone, Edinburgh, pp. 225-277, 1986.

42. Shorter, R G., et al, A working hypothesis for the etiology and pathogenesis of nonspecific inflammatory bowel disease, Am. J. Dig. Dis., 17: 1024-1032, 1972.

43. Jackson, P. G., et al, Intestinal permeability in patients with eczema and food allergy, Lancet, 1:1285-1286, 1981.

Special Recognition to Dr. Resnik whose studies contributed to this research.


Pure Health Systems BBB Business Review

PURE HEALTH SYSTEMS
Jeffrey T. Maehr, D.C. (Ret.)
Certified Nutritional Microscopist
Wholistic Nutritional Consultant

Email: drhealth (at) purehealthsystems (dot) com
970-731-9724

Disclaimer: Please note that the nature of the Internet is such that on occasion, there are server failures or other technical difficulties that can affect the functioning of the shopping cart system. PHS is not responsible for any improper charges except to refund any over charges that do not properly reflect the price for any individual product. Should any under charge occur, you have the option to be billed for the balance, or to be refunded all charges incurred.

The information given within these pages is designed to help you make informed decisions about your health. It is not intended as a substitute for the advice or treatment that may have been prescribed by your physician. Please remember that true health involves addressing all the systems of the body, and not just using one particular product as your hope for good health. Before adhering to any of the information or recommendations, you may want to consult with your personal health care professional. Understand that you are solely responsible for the way that this information is perceived and utilized, and do so at your own risk. In no way will Pure Health Systems or Jeffrey T. Maehr be responsible for any injuries or problems that might occur due to the use of this web site, the advice contained within or the products offered. IF YOU HAVE QUESTIONS, PLEASE ASK YOUR HEALTH CARE PRACTITIONER!

These statements have not been reviewed by the FDA. Products are not intended to diagnose, treat, cure or prevent any disease.


Common Law Copyright © 2012 Jeffrey T. Maehr. All rights reserved. No reproduction in any form, or use without written consent of author, unless material is referenced to Pure Health Systems web site. Other outside linked pages and Copyright listed accordingly!
image